| Identification | More | [Name]
3,3-Dimethyl-D(-)-cysteine | [CAS]
52-67-5 | [Synonyms]
3,3-DIMETHYL-D(-)-CYSTEINE
3,3-DIMETHYL-D-CYSTEINE
3-MERCAPTO-D-VALINE
D(-)-2-AMINO-3-MERCAPTO-3-METHYLBUTANOIC ACID
D[-]-2-AMINO-3-MERCAPTO-3-METHYLBUTANOIC ACID
D-BETA,BETA-DIMETHYLCYSTEINE
D-BETA-MERCAPTOVALINE
DISTAMINE
D-(-)-PENICILLAMINE
D-PENICILLAMINE
H-D-PEN-OH
PENICILLAMINE
PENICILLAMINE(D-)
(S)-2-AMINO-3-MERCAPTO-3-METHYL-BUTYRIC ACID
(S)-Penicillamin
(S)-Penicillamine
3-mercapto-d-valin
3-Sulfanylvaline
alpha-amino-beta-methyl-beta-mercaptobutyricacid
Artamine | [EINECS(EC#)]
200-148-8 | [Molecular Formula]
C5H11NO2S | [MDL Number]
MFCD00064302 | [Molecular Weight]
149.21 | [MOL File]
52-67-5.mol |
| Chemical Properties | Back Directory | [Appearance]
White to off-white crystalline powder | [Melting point ]
210 °C (dec.)(lit.)
| [alpha ]
-65 º (c=5, 1M NaOH, on dry) | [Boiling point ]
251.8±35.0 °C(Predicted) | [density ]
1.113 (estimate) | [refractive index ]
-63 ° (C=1, 1mol/L NaOH) | [storage temp. ]
2-8°C
| [solubility ]
H2O: soluble100mg/mL | [form ]
Powder | [pka]
pKa 7.83±0.01(H2O,t =37±0.05,I=0.15)(Approximate) | [color ]
White to almost white | [Stability:]
Stable. Incompatible with strong oxidizing agents. | [Water Solubility ]
11.1 g/100 mL (20 ºC) | [Merck ]
14,7088 | [BRN ]
1722375 | [InChIKey]
VVNCNSJFMMFHPL-VKHMYHEASA-N | [CAS DataBase Reference]
52-67-5(CAS DataBase Reference) | [NIST Chemistry Reference]
Penicillamine(52-67-5) | [EPA Substance Registry System]
52-67-5(EPA Substance) |
| Safety Data | Back Directory | [Hazard Codes ]
Xi,T,Xn | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin .
R40:Limited evidence of a carcinogenic effect.
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36:Wear suitable protective clothing .
S24/25:Avoid contact with skin and eyes .
S22:Do not breathe dust . | [WGK Germany ]
2
| [RTECS ]
YV9425000
| [Hazard Note ]
Toxic | [HS Code ]
29309016 | [Safety Profile]
Poison by
intraperitoneal route. Moderately toxic by
subcutaneous and intravenous routes. Mildly
toxic by ingestion. An experimental
teratogen. Human systemic effects by
ingestion: agranulocytosis, dermatitis, fever,
hemorrhage, increased body temperature,
dermatitis, leukopenia, proteinuria,
thrombocytopenia. Human teratogenic
effects by an unspecified route:
developmental abnormalities of the
craniofacial areas, skin, and skin appendages,
and body wall. Experimental reproductive
effects. Questionable human carcinogen
producing leukemia. Mutation data reported.
Used in the treatment of rheumatoid
arthritis, metal poisonings, and cystinuria.
When heated to decomposition it emits very
toxic fumes of NOx and SOx. See also
MERCAPTANS. | [Hazardous Substances Data]
52-67-5(Hazardous Substances Data) | [Toxicity]
LD50 in rats (mg/kg): >10000 orally, >660 i.p. (Jaffe) |
| Raw materials And Preparation Products | Back Directory | [Raw materials]
Penicillin G potassium salt-->Phenylhydrazine-->Sodium hydroxide-->Mercury chloride-->Hydrogen Sulfide-->4-Thiazolidinecarboxylic acid, 5,5-dimethyl-2-[2-oxo-1-[(phenylacetyl)amino]-2-[(2-phenylethyl)amino]ethyl]-, [2R-[2α(R*),4β]]- (9CI)-->4-Thiazolidinecarboxylic acid, 5,5-dimethyl-2-[[(2-phenylacetyl)amino]methyl]-, (2R,4S)--->2-Aminobenzenethiol-->p-Phenylenediamine | [Preparation Products]
N-ACETYL-3-MERCAPTO-D-VALINE-->(S)-FMOC-5,5-DIMETHYL-1,3-THIAZOLIDINE-4-CARBOXYLIC ACID |
| Questions And Answer | Back Directory | [Description]
D-penicillamine (DPA) is a heavy metal chelator and is the drug of choice for management of Wilson’s disease, a copper-overload disease state. It may also be effective in arsenic, mercury, and lead chelation. Although the toxicity of DPA is relatively low, there are more effective and less toxic chelators, for most heavy metals, with the exception of copper. | [uses]
D-Penicillamine is used as an antirheumatic to reduce the number of T cells, to inhibit microphages by reducing the activity of Interleukin and rheumatoid factor, and to prevent crosslinking of the collagen.
It is used as a chelating agent in Wilson's disease.It is used mainly as chelating agent in heavy metal poisoning as in lead, mercury and copper poisoning. It is also used for therapy in progressive systemic sclerosis. | [Biochem/physiol Actions]
Penicillamine is a characteristic degradation product of penicillin type antibiotics. One atom of copper combines with two molecules of penicillamine. Penicillamine reduces excess cystine excretion in cystinuria. This is by disulfide interchange between penicillamine and cystine, which results in formation of a readily excreted penicillamine-cysteine disulfide. Penicillamine interferes with the formation of cross-links between tropocollagen molecules and cleaves them when newly formed. Penicillamine lowers IgM rheumatoid factor and depresses T-cell activity. | [Mechanism of Action]
Penicillamine chelates heavy metals including copper, iron, lead, and mercury, forming stable complexes that can then be excreted by the kidneys. One gram of penicillamine has the potential to combine with 200 mg of copper. When administered to patients with Wilson's disease, however, a 1 gm dose of penicillamine results in excretion of only 2 mg of copper.Penicillamine complexes with cystine, forming penicillamine-cysteine disulfide. This compound is more soluble than cysteine-cysteine disulfide (cystine), thereby reducing the levels of free urinary cystine below those considered crucial to the formation of cystine stones. Existing stones also may undergo dissolution during penicillamine therapy.Penicillamine's antirheumatic action may be due, in part, to the drug's ability to inhibit the formation of collagen. Penicillamine also appears to depress circulating levels of IgM rheumatoid factor, but, in contrast to cytotoxic immunosuppressants, the drug does not reduce the absolute levels of serum immunoglobulins. Penicillamine depresses T-cell activity but not B-cell activity. | [Pharmacokinetics]
Penicillamine is administered orally. The distribution of penicillamine is not well known, but it is believed to cross the placenta. Protein binding is about 80%, primarily to albumin. The drug also binds to erythrocytes and macrophages. Penicillamine appears in the plasma as free penicillamine, penicillamine disulfide, and cysteine-penicillamine disulfide. A small fraction of the dose is metabolized in the liver to s-methyl-D-penicillamine. Drug excretion is primarily renal, mainly as disulfides. One study determined that, of a total dose of penicillamine, approximately 50% was excreted in the urine and 20% in the feces. Approximately 30% of the drug remained unaccounted for. When prolonged treatment is stopped, there is a slow elimination phase lasting 4—6 days. | [Side Effects]
More common
Fever
joint pain
lesions on the face, neck, scalp, and/or trunk
skin rash, hives, or itching
swollen and/or painful glands
ulcers, sores, or white spots on lips or in mouth
Less common
Bloody or cloudy urine
shortness of breath, troubled breathing, tightness in chest, or wheezing
sore throat and fever with or without chills
swelling of face, feet, or lower legs
unusual bleeding or bruising
unusual tiredness or weakness
https://www.mayoclinic.org/drugs-supplements/penicillamine-oral-route/side-effects/drg-20065377
https://www.drugs.com/mtm/penicillamine.html | [Reference]
- A. J. Dixon, J. Davies, T. L. Dormandy, E. B. Hamilton, P. J. Holt, R. M. Mason, M. Thompson, J. C. Weber, D. W. Zutshi, Synthetic D(-)penicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low dosage regimen, Annals of the Rheumatic Diseases, 1975, vol. 34, pp. 416-421
- V. D. Steen, T. A. Medsger, G. P. Rodnan, D-Penicillamine Therapy in Progressive Systemic Sclerosis (Scleroderma): A Retrospective Analysis, 1982, vol. 97, pp. 652-659
|
| Hazard Information | Back Directory | [Chemical Properties]
White to off-white crystalline powder | [Originator]
Cuprimine,MSD,US,1963 | [Uses]
As a Penicillin metabolite, D-(-)-Penicillamin can be used in the treatment of Wilson’s disease, Cystinuria, Scleroderma and arsenic poisoning.
| [Uses]
chelating agent (Cu), antirheumatic | [Uses]
D-(-)-Penicillamin is used as an antirheumatic and as a chelating agent in Wilson′s disease. It is used as a copper chelator to form mixed disulfides with cysteine or other sulfide media components. It is used to inactivate protein-1 DNA binding and to inhibit the growth of asynchronous cultures of rabbit articular chondrocytes.
| [Definition]
ChEBI: An optically active form of penicillamine having D-configuration. Pharmaceutical form (L-form is toxic) of chelating agent used to treat heavy metal poisoning. | [Manufacturing Process]
(a) Preparation of mercuric chloride complex of penicillamine: To a solution of 372 g (1 mol) of potassium benzyl-penicillin in 940 ml of distilled water at room temperature is added a solution of 40 g (1 mol) of sodium hydroxide in 180 ml of distilled water over a period of one-half hour. The solution is then stirred for two hours at room temperature. While maintaining room temperature, 67 ml of concentrated hydrochloric acid is added at a slow rate. This solution is then added, over a period of time of one-half hour, to a solution of 271 g (1 mol) of HgCl2 in 3.52 liters of distilled water in the presence of 50 g of Hyflo and 5 ml of octyl alcohol. After one hour of agitation, the resulting mixture is treated with 185 ml of concentrated hydrochloric acid and filtered.
(b) Removal of benzylpenilloaldehyde: To the filtrate obtained in step (a), warmed to 50°C is slowly added 108 g (1 mol) of phenyl hydrazine. The mixture is cooled to room temperature and 84 ml of concentrated hydrochloric acid are added. The mixture is agitated briefly and the precipitated benzylpenilloaldehyde phenyl hydrazone is filtered off.
(c) Preparation of isopropylidene penicillamine hydrochloride: To the filtrate obtained in step (b) is added at 20°C to 25°C a total of 85 g of hydrogen sulfide. The precipitated HgS is filtered off and the filtrate is concentrated under reduced pressure to a volume of 200 to 500 ml. Following a polish filtration, the product-rich concentrate is mixed with 1.5 liters of isobutyl acetate. The mixture is refluxed at about 40°C under reduced pressure in equipment fitted with a water separation device. When no further water separates, the batch is cooled to 30°C and filtered. The reactor is washed with 1 liter of acetone, which is used also to wash the cake. The cake is further washed with 200 ml of acetone. The acetone washes are added to the isobutyl acetate filtrate and the mixture is refluxed for 20 to 30 minutes. After a holding period of one hour at 5°C. the crystals of isopropylidene penicillamine hydrochloride are filtered and washed with 200 ml of acetone. On drying for twelve hours at 25°C this product, containing 1 mol of water, weighs about 178 g (73%).
(d) Preparation of penicillamine hydrochloride: The 178 g of isopropylidene penicillamine hydrochloride obtained in step (c) is dissolved in 350 ml of distilled water. The solution is heated at 90°C to 95°C for one to one and onehalf hours, removing acetone by distillation through an efficient column. There is then added 2.6 liters of isobutyl acetate. The mixture is refluxed at a temperature of about 40°C under reduced pressure in equipment fitted with a water separation device. When no further water separates, the pressure is adjusted so that the mixture distills at a vapor temperature of 83°C to 88°C. A total of 650 ml of distillate is collected. The batch is allowed to cool to 50°C and then filtered. The crystals are washed with isobutyl acetate and then dried at 35°C for 24 hours. The virtually anhydrous penicillamine hydrochloride obtained weighs about 128 g (69% from potassium benzyl-penicillin).
| [Brand name]
Cuprimine(Merck); Depen (Medpointe). | [Therapeutic Function]
Antiarthritic | [General Description]
D-Penicillamine contains a β-lactam chemical structure. | [Clinical Use]
Rheumatoid arthritis, Wilson’s disease, cystinuria, lead
poisoning, chronic active hepatitis | [Drug interactions]
Potentially hazardous interactions with other drugs
Antipsychotics: avoid with clozapine (increased risk
of agranulocytosis).
Sodium aurothiomalate: increased risk of
haematological toxicity | [Metabolism]
Penicillamine undergoes limited metabolism in the liver,
to S-methyl penicillamine.
It is mainly excreted in the urine as disulfides, along with
some S-methyl penicillamine and unchanged drug; a small
amount may be excreted in the faeces | [Purification Methods]
The melting point of D-(-)-penicillamine depends on the rate of heating (m 202-206o is obtained by starting at 195o and heating at 2o/minute). It is soluble in H2O and alcohols but insoluble in Et2O, CHCl3, CCl4 and hydrocarbon solvents. Purify it by dissolving it in MeOH and adding Et2O slowly. Dry it in vacuo and store it under N2. [Weight et al. Angew Chem, Int Ed (English) 14 330 1975, Cornforth in The Chemistry of Penicillin (Clarke, Johnson and Robinson eds) Princeton Univ Press, 455 1949, Review: Chain et al. Antibiotics (Oxford University Press) 2 1949, Polymorphism: Vidler J Pharm Pharmacol 28 663 1976]. The D-S-benzyl derivative has m 197-198o (from H2O), [] D 17 -20o (c 1, N NaOH), -70o (N HCl). [Beilstein 4 IV 3228.] |
|
|